Figure 3. DAGLβ is a principal 2-AG biosynthetic enzyme in microglia.

(A–C) 2-AG, AA, and PGE₂/D₂ content in primary neurons (A), astrocytes (B), and microglia (C) derived from Dagla^–/–, Daglb^–/– and corresponding wild-type mice. Data represent average values ± SEM; N = 5–8 per genotype. **p < 0.01 for Dagla^–/– or Daglb^–/– groups vs corresponding wild-type groups.

DOI: http://dx.doi.org/10.7554/eLife.12345.008

Figure 3—figure supplement 1. Pharmacological blockade of DAGLβ modulates eCB/eicosanoid metabolism in microglia.

(A–C) 2-AG (A), AA (B), and PGE₂/D₂ (C) content in wild-type microglia treated with vehicle, the DAGLβ inhibitors KT109 (500 nM, 4 hr) or KT172 (500 nM, 4 hr), or the inactive control compound (KT195, 500 nM, 4 hr). Data represent average values ± SEM; N = 5 per treatment. **p < 0.01 for inhibitor-treated groups vs corresponding vehicle-treated groups.

DOI: http://dx.doi.org/10.7554/eLife.12345.009